Navigation Links
Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
Date:2/4/2010

RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.  

Dr. Painter has more than 20 years of experience in the pharmaceutical industry, including work in clinical development, clinical safety and pharmacovigilance, and occupational and environmental medicine.  In her role as Chief Medical Officer, Dr. Painter will be responsible for clinical strategy and development of Chimerix's proprietary antiviral medicines addressing life-threatening diseases.  Dr. Painter has been working with Chimerix since 2002 in a consulting capacity, providing medical oversight and clinical consulting.  

"We are delighted to have Wendy join our leadership team.  Her extensive background in all phases of antiviral drug development has been and will be invaluable as we advance our pipeline through the clinical trials process," said Kenneth I. Moch, Chimerix's Chief Operating Officer.  "Wendy has been a vital force in the development of our broad-spectrum antiviral candidate CMX001."

Dr. Painter has an extensive background in drug development at a number of biotechnology and pharmaceutical companies.  Her experience includes having served as Medical Director at GlaxoSmithKline (GSK) where she had responsibility for worldwide antiviral clinical safety.  While there, she was involved in a number of antiviral Investigational New Drug (IND) applications and New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.  Subsequently, she provided expert medical consulting to a range of biotechnology and pharmaceutical companies regarding drug development.  Dr. Painter earned an M.S. in Organic Chemistry at Emory University and an M.D. degree at the University of Miami School Of Medicine.  She later obtained a Master of Public Health degree in Epidemiology at the University of North Carolina at Chapel Hill and completed a fellowship in occupational medicine at Duke University where she maintains an academic appointment.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, in addition to significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.

RELATED LINKS
http://www.chimerix-inc.com

'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. KGI Names Kerry Howell Vice President for Advancement
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. Genstar Names Michael Hurt to Its Strategic Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... Charm Sciences, Inc. is pleased to announce that its Charm ... appropriate as a screening test at dairies and farms for raw commingled cow milk. ... Charm EZ Lite system. These systems are a combination incubator and reader in one. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found ... latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, ... effect on men. ”The logical next step, in my estimation, was to scientifically track ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):